Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Acquired by BML Capital Management LLC

BML Capital Management LLC increased its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 3.0% during the third quarter, Holdings Channel.com reports. The fund owned 1,136,091 shares of the company’s stock after acquiring an additional 33,196 shares during the quarter. Milestone Pharmaceuticals accounts for approximately 1.0% of BML Capital Management LLC’s investment portfolio, making the stock its 16th largest position. BML Capital Management LLC’s holdings in Milestone Pharmaceuticals were worth $1,727,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in Milestone Pharmaceuticals by 177.0% in the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock worth $30,000 after acquiring an additional 10,800 shares in the last quarter. Valeo Financial Advisors LLC raised its position in Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after acquiring an additional 10,000 shares in the last quarter. Atria Investments Inc raised its position in Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares in the last quarter. Finally, Lion Point Capital LP raised its position in Milestone Pharmaceuticals by 1.7% in the second quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock worth $3,089,000 after acquiring an additional 40,000 shares in the last quarter. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Stock Down 1.0 %

NASDAQ:MIST traded down $0.02 on Tuesday, hitting $1.92. 67,554 shares of the company’s stock traded hands, compared to its average volume of 226,993. The company has a current ratio of 19.13, a quick ratio of 19.13 and a debt-to-equity ratio of 1.61. Milestone Pharmaceuticals Inc. has a 1 year low of $1.12 and a 1 year high of $3.52. The firm has a 50-day moving average price of $1.52 and a 200-day moving average price of $1.51. The company has a market cap of $102.28 million, a PE ratio of -1.90 and a beta of 1.72.

Analyst Ratings Changes

MIST has been the topic of several research reports. Rodman & Renshaw initiated coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 22nd. They issued a “buy” rating and a $9.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Monday, October 14th.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.